ARRIVENT BIOPHARMA, INC. Proceeds from Issuance of Convertible Preferred Stock
ARRIVENT BIOPHARMA, INC. (AVBP) reported Proceeds from Issuance of Convertible Preferred Stock of $44.92 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2025-03-03
- ARRIVENT BIOPHARMA, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2023-12-31 was $0.00.
- ARRIVENT BIOPHARMA, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2023-09-30 was $0.00.
- ARRIVENT BIOPHARMA, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2023-06-30 was -$24.00K.
- ARRIVENT BIOPHARMA, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2023-03-31 was $44.94M.
- ARRIVENT BIOPHARMA, INC. proceeds from issuance of convertible preferred stock for fiscal 2023 was $44.92M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | -$24.00K derived: sum of 3 quarters · filed 2025-03-03 | $44.92M 10-K · filed 2025-03-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$24.00K derived: sum of 2 quarters · filed 2024-11-14 | $44.92M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $44.92M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $44.94M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |